Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• The patient is scheduled for non-emergent CABG surgery.

• CyC eGFR or MDRD eGFR < 60 ml/min.

• The patient has given his/her written consent to participate

Exclusion Criteria:

• The patient has an uncontrolled hypertension.

• Hypersensitivity to the active drug.

• The patient is pregnant or is a fertile woman (<50 years).

• The patient has been treated with Erythropoietin within 4 weeks prior to the surgery.

• Preoperative CyC eGFR or MDRD eGFR is < 15, or the patient is treated with dialysis.

• The patient has a known malignancy.

• The patient is planned for Off-pump CABG surgery.

• The patient is included in other ongoing clinical trial. Yes / No

• Clinically judgment by the investigator that the patient should not participate in the study.